by Claudia Li | May 10, 2023 | Press Releases
Press release DiaCarta Receives Accreditation by the College of American Pathologists (CAP) FollowFollow DiaCarta, Ltd. (“DiaCarta”), a novel molecular diagnostic test developer for cancer and infectious diseases, today announced that it has received accreditation by...
by Claudia Li | Apr 17, 2023 | Press Releases
Press release DiaCarta Announces Five Abstracts Accepted for Presentation at AACR Annual Meeting 2023 FollowFollow Abstracts demonstrating XNA technology’s improvements to assay sensitivity across different technology platforms and support for use in companion...
by Claudia Li | Jan 12, 2023 | Press Releases
Press release DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit FollowFollow Pleasanton, California – Jan. 10, 2023 – DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that the U.S. Food and Drug...
by Claudia Li | Jan 5, 2023 | Press Releases
Press release DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience FollowFollow DiaCarta Starts to Receive Samples for Oncuria® Bladder Cancer Test at its CLIA Lab PLEASANTON, CA and LOS ANGELES, CA—January 5, 2023—DiaCarta,...
by Claudia Li | Oct 14, 2022 | Press Releases
Press release DiaCarta to Become a Publicly Listed Company Through Merger with HH&L Acquisition Co. FollowFollow PLEASANTON, Calif. & HONG KONG DiaCarta, Ltd. (“DiaCarta” or the “Company”), a precision molecular diagnostics company and developer of novel...
by Claudia Li | Jul 20, 2022 | Press Releases
Press release Home ❯News & Events❯Press Releases❯ You are here ❯ Home ❯ Search ❯ RadTox ❯ DiaCarta Receives CE-IVD Mark for Its SARS-CoV-2 Flu A/B Combo Test FollowFollow PLEASANTON, Calif., July 20, 2022 DiaCarta Inc., a precision molecular diagnostics company and...
Recent Comments